Print

Incyte Corporation (INCY) Drug Jakafi® (ruxolitinib) Improved Overall Survival in Phase III Trial of Patients With Myelofibrosis  
6/17/2013 9:37:53 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

STOCKHOLM--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) today announced results from two ongoing clinical trials of JakafiĀ® (ruxolitinib), an oral JAK1 and JAK2 inhibitor that is FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), that were presented at the 18th Congress of the European Hematology Association (EHA) in Stockholm, Sweden. In a three-year follow-up analysis of the Phase III COMFORT-II study, treatment with Jakafi, which is marketed as JakaviĀ® by Novartis outside the United States, was associated with improved overall survival and sustained reductions in spleen size compared to best available therapy. In a separate exploratory analysis of bone marrow fibrosis data from an ongoing Phase I/II single-arm, open-label clinical trial, by 48 months of treatment, Jakafi stabilized or reversed fibrosis of the bone marrow in 56 percent and 22 percent, respectively, of patients with MF, a magnitude of an effect not seen historically with best available therapy.

Help employers find you! Check out all the jobs and post your resume.

//-->